Top

BY Clayton Boldt, Ph.D.

Advanced ovarian cancer most commonly metastasizes to the omentum, a layer of fatty tissue that wraps around and protects internal organs in the abdomen, but the reasons for this have not been well-understood. In a new study, MD Anderson researchers discovered that a protein called omentin, or ITLN1, works to prevent metastasis of the cancer cells, but it is lost as the cancer develops.

Their preclinical findings, published in...

Imaging mass spectrometry showing increased abundance of ATP, a cellular energy compound, in the omentum of mice after injection with omentin protein.

BY Clayton Boldt, Ph.D.

The American Association for Cancer Research (AACR) is recognizing the founding members of The Cancer Genome Atlas (TCGA)&nbsp...

BY Clayton Boldt, Ph.D.

MD Anderson researchers have discovered that metastatic cancer cells in the brain upregulate expression of the EZH2 gene to activate a previously...

BY Clayton Boldt, Ph.D.

Brian Odle has now overcome four cancer diagnoses in his life, thanks to inheriting a mutation in the TP53 gene. This inherited condition is known as Li-Fraumeni Syndrome and puts carriers at an increased risk of several cancer types.

By summer 2019, Brian had been successfully treated for a large germ cell tumor, melanoma and osteosarcoma. However, that summer he began feeling poorly, and his MD Anderson care team ordered a bone...

Cancer cells and antibodies

BY Clayton Boldt, Ph.D.

Julia Pitts tried all the standard treatment options with her local physicians after she was diagnosed with metastatic uterine cancer in 2015...

BY Clayton Boldt, Ph.D.

In an analysis of three clinical trials, the targeted therapy larotrectinib resulted in a 79% overall response rate and median overall survival...

BY Clayton Boldt, Ph.D.

A deep sequencing study of brain metastases from MD Anderson revealed many similarities but also distinct differences relative to the primary...

BY Clayton Boldt, Ph.D.

In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy...

BY Clayton Boldt, Ph.D.

Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy...

BY Clayton Boldt, Ph.D.

Immunotherapies have brought the potential for long-term remission and even cures to patients with many cancer types, but the benefits have...